Gustav Christensen

Gustav Christensen is chairman of Morphic Therapeutic, a public biotech company. He was president and chief executive officer of Dyax Corp (NASDAQ: DYAX) from January 1, 2009 until it was acquired by Shire for $6.4 billion in January 2016. He joined Dyax in early 2007 as executive vice president and chief business officer. Gustav began his career at Baxter International, with his last position being vice president of operations of the Fenwal Laboratories division. He left in 1983 to become the vice president of business development at the Genetics Institute from 1983 to 1988. Mr. Christensen received his Master of Science in economics from the University of Aarhus, Denmark and his Master of Business Administration from Harvard Business School.